ClinicalTrials.gg
CompletedNCT03520517Updated Oct 6, 2022

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

A Phase 1 interventional study of BHV-0223 in Amyotrophic Lateral Sclerosis, ALS and Lou Gehrig Disease, sponsored by Biohaven Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-06.

Sponsored by Biohaven Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2018, 8 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
190th of 307
22 · median 33
Started
2018
with 19 others
Phase 1
57 of 440
11 open now
Registered
216th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 190th largest by enrollment of the 307 interventional ones that give a count, is one of 20 that started in 2018, is one of 57 in phase 1, and was the 216th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

Phase 1, open-label study of BHV-0223 in ALS.

Read the detailed description

This is a phase 1, open-label, single arm study to evaluate the safety, tolerability and pharmacokinetics of multiple doses of BHV-0223 in subjects with ALS.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • ALS
  • Lou Gehrig Disease
  • Lou Gehrig's Disease
  • Lou-Gehrigs Disease
  • Motor Neuron Disease, Amyotrophic Lateral Sclerosis

Keywords

  • Amyotrophic Lateral Sclerosis
  • ALS
  • Biohaven
  • Motor Neuron Disease, Amyotrophic Lateral Sclerosis
  • Lou Gehrig's Disease
  • Lou-Gehrigs Disease
  • Lou Gehrig Disease
  • Riluzole
  • Rilutek®
  • Neuroprotective Agents
  • Administration, Sublingual
  • Administration, Oral
  • Biological Availability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with diagnosed ALS by the revised El Escorial diagnostic criteria, including laboratory supported probable, probable, or definite ALS;
  2. Subjects who have never taken riluzole tablets, OR Subjects who previously took riluzole tablets but discontinued at least 1 month prior to the screening visit. Subjects must not have had or AST > 5 x while taking riluzole tablets, or any other tolerability issues (e.g., reactions) in the judgement of the investigator;
  3. Subjects determined by the investigator to be medically stable;
  4. Subjects determined by the investigator to be willing and physically able to complete the study as designed, with or without caregiver assistance.

Exclusion criteria

Exclusion Criteria:

  1. Target Disease Exceptions
  2. Medical History Exceptions

    1. Subject is known to have a current diagnosis of acute or chronic viral hepatitis;
    2. Subject is known to have any other acute or chronic liver disease that is in the investigator's judgment;
    3. Subject has a history of a clinically significant medical condition that would interfere with the subject's ability to comply with study instructions, would place the subject at increased risk, or might confound the interpretation of the study results in the investigator's judgment;
    4. Any other sound medical, psychiatric and/or social reason in the investigator's judgment;
  3. Physical and Laboratory Test Findings

    1. Positive urine pregnancy test in at screening;
    2. Subject has evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, or other determinations beyond what is consistent with the target population, in the investigator's judgment;
    3. Subject has liver function testing abnormalities (, AST , or total ) that are > 1 x ;
  4. Other Exclusions a. Subjects who are unable to be compliant with the visit schedule or protocol procedures.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    BHV-0223

    riluzole 40 mg sublingual tablet

    Drug: BHV-0223

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)

    Incidence of treatment emergent adverse events (safety and tolerability) as measured through laboratory tests and physical exam findings.

    Time frame: Through Week 8 (Day 57)

Secondary outcomes

  1. BHV-0223 Concentrations in Blood at Days 1, 29 and 57

    BHV-0223 concentrations at days 1, 29 and 57 through blood collections at days 1, 29 and 57.

    Time frame: Through Week 8 (Day 57)

07

Study locations

5 sites
  • Holy Cross Neuroscience Research Institute
    Fort Lauderdale, Florida 33334, United States
  • Somnos/Neurology Associates Clinical Research
    Lincoln, Nebraska 68506, United States
  • Neurosciences Institute, Neurology - Charlotte
    Charlotte, North Carolina 28207, United States
  • Wesley Neurology Clinic
    Cordova, Tennessee 38018, United States
  • Texas Neurology
    Dallas, Texas 75214, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Oct 2018, 8 months.

Of 40 industry-sponsored phase 1 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's 8 months is below that.

Counting every sponsor, half of 70 studies reached it within 21 months; a quarter within 13 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2018
First posted
May 9, 2018
StartActual
Feb 2, 2018
Primary completionActual
Oct 8, 2018
CompletionActual
Oct 8, 2018
Last update
Oct 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03520517
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Collaborators
Cognitive Research Corporation
Responsible party
Sponsor
First posted
May 9, 2018
Start date
Feb 2, 2018
Primary completion
Oct 8, 2018
Completion
Oct 8, 2018
Last update
Oct 6, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riluzole

Start the discussion